RBC Capital Initiates Coverage On Tandem Diabetes Care with Outperform Rating, Announces Price Target of $65
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has initiated coverage on Tandem Diabetes Care with an Outperform rating and set a price target of $65.
October 02, 2024 | 9:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has initiated coverage on Tandem Diabetes Care with an Outperform rating and a price target of $65, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $65 by RBC Capital suggests a positive sentiment towards Tandem Diabetes Care. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100